VMD Sciences launches global veterinary export pharmacy

VMD Sciences on June 23 launched a Global Veterinary Export Pharmacy and Veterinary Managed Access Programs to give veterinarians outside the U.S. regulated access to U.S.-sourced medicines and vaccines. The company says the service is aimed at shortages, emerging diseases and unmet treatment needs in animal health.

Why it matters: - VMD Sciences is trying to narrow a long-standing access gap between human and veterinary medicine. - The new export pharmacy and VMAPs are designed to give veterinarians a compliant path to medicines when local supply, approval status or commercial availability falls short. - The launch could matter most during drug shortages, emerging disease outbreaks and cases of unmet treatment need.

What happened: - VMD Sciences launched its Global Veterinary Export Pharmacy and introduced Veterinary Managed Access Programs, or VMAPs. - The announcement came June 23, 2026, from the company’s base in Austin, Texas. - The new pharmacy and services operate from Lake Worth, Florida. - Ricky Falcha, president of VMD Sciences, said the company aims to close a gap that human medicine addressed years ago. - Dr. Wendy Vaala, VMD, DACVIM (LAIM), chief veterinary officer, said VMAPs are meant to elevate standard-of-care through country-specific, regulatory-compliant access.

The details: - The export pharmacy gives veterinary practices, clinics and distributors outside the United States access to U.S.-sourced FDA- and USDA-approved medications through compliant export channels. - VMD Sciences says the service complements its existing global drug and vaccine importation work for veterinarians in the United States. - VMAPs are modeled on human Managed Access Programs. - VMAPs can provide access to investigational therapies, specialized formulations and treatments for rare or complex conditions before broad availability or full approval. - The programs are intended to support urgent clinical needs while staying within regulatory requirements. - VMD Sciences says VMAPs can be deployed with pharmaceutical companies across different stages of a product’s lifecycle. - The company says it is the first to provide veterinarians worldwide compliant access to essential medicines and antimicrobials listed by the World Small Animal Veterinary Association, the World Veterinary Association, BROOKE and the World Organisation for Animal Health. - The groups represented by those lists include more than 500,000 veterinarians in more than 180 countries. - The essential medicines lists are modeled on the World Health Organization’s human essential medicines framework. - The lists identify core drugs needed for minimum standards of care and treatment for common and urgent diseases. - VMD Sciences also says its offerings cover medicines and vaccines needed to help with unmet medical needs, emerging diseases and drug shortages in local markets.

Between the lines: - The launch reflects a broader push to apply human-style access frameworks to veterinary care. - The company is positioning regulatory compliance as the central selling point, not just product availability. - If adopted widely, VMAPs could become a channel for faster cross-border access to animal health therapies that are delayed or unavailable in many countries.

What's next: - VMD Sciences is directing veterinary professionals, manufacturers and distributors to contact the team through LinkedIn or at vmdsciences.com. - The company says it will work with industry partners to expand access through Global Pharmacy Export Services and VMAPs. - VMD Sciences says its broader business will continue to focus on importation, VMAPs, real-world data support and global export services.

The bottom line: - VMD Sciences is building a regulated international supply route for veterinary medicines, with the goal of making critical animal treatments easier to access across borders.